Advisors Asset Management, Inc. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Advisors Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2022	SELL	$144.95 - $152.29 $80,447 - $84,520	-555 Reduced 6.4%	8,117 $1.23 Million
Q2 2022 Aug 08, 2022	SELL	$83.14 - $145.99 $1.24 Million - $2.18 Million	-14,966 Reduced 63.31%	8,672 $1.26 Million
Q1 2022 May 17, 2022	SELL	$110.08 - $142.92 $155,543 - $201,945	-1,413 Reduced 5.64%	23,638 $2.8 Million
Q4 2021 Feb 15, 2022	BUY	$99.73 - $148.48 $19,048 - $28,359	191 Added 0.77%	25,051 $3.45 Million
Q3 2021 Nov 12, 2021	BUY	$98.85 - $138.91 $81,551 - $114,600	825 Added 3.43%	24,860 $3.45 Million
Q2 2021 Jul 30, 2021	BUY	$65.78 - $105.02 $146,820 - $234,404	2,232 Added 10.24%	24,035 $2.33 Million
Q1 2021 May 07, 2021	BUY	$64.07 - $91.75 $87,647 - $125,514	1,368 Added 6.69%	21,803 $1.49 Million
Q4 2020 Feb 12, 2021	BUY	$65.07 - $98.24 $413,454 - $624,216	6,354 Added 45.12%	20,435 $1.75 Million
Q3 2020 Nov 16, 2020	BUY	$59.04 - $77.95 $529,234 - $698,743	8,964 Added 175.18%	14,081 $915,000
Q2 2020 Aug 12, 2020	BUY	$29.01 - $74.23 $148,444 - $379,834	5,117 New	5,117 $374,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisors Asset Management, Inc. with notifications on news.